P308 Strategies for the screening of glucose tolerance abnormalities and diabetes in people with cystic fibrosis: a French position statement

Abstract

The increase in life expectancy of people with cystic fibrosis (pwCF) has come with new comorbidities, particularly diabetes. Cystic fibrosis related diabetes is a major challenge in the care of (pwCF) because it is a morbidity and mortality factor at all stages of the disease. Early glucose tolerance abnormalities observed from childhood are also associated with a poor pulmonary and nutritional outcome. This justifies systematic screening with an annual oral glucose tolerance test (OGTT) from the age of 10 years.